93 related articles for article (PubMed ID: 8763810)
21. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
22. Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.
Kim S; Chung HW; Kong HY; Lim JB
Yonsei Med J; 2017 Jan; 58(1):43-50. PubMed ID: 27873494
[TBL] [Abstract][Full Text] [Related]
23. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
Hasegawa K; Ikeda Y; Kunugi Y; Kurosaki A; Imai Y; Kohyama S; Nagao S; Kozawa E; Yoshida K; Tsunoda T; Nakamura Y; Fujiwara K
J Immunother; 2018 May; 41(4):201-207. PubMed ID: 29432282
[TBL] [Abstract][Full Text] [Related]
24. Generation of cytotoxic T cells to cytomegalovirus in patients with cervical intraepithelial neoplasia.
Neill WA; Miller EP
Med Lab Sci; 1987 Apr; 44(2):141-9. PubMed ID: 2826963
[No Abstract] [Full Text] [Related]
25. Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer.
Gissmann L; Jochmus I; Nindl I; Müller M
Ann N Y Acad Sci; 1993 Aug; 690():80-5. PubMed ID: 8396380
[No Abstract] [Full Text] [Related]
26. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
[TBL] [Abstract][Full Text] [Related]
27. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens.
Kaufmann AM; Gissmann L; Schreckenberger C; Qiao L
Cancer Gene Ther; 1997; 4(6):377-82. PubMed ID: 9408608
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer.
Jang S; Kim YT; Chung HW; Lee KR; Lim JB; Lee K
Cancer; 2012 Apr; 118(8):2173-83. PubMed ID: 21918960
[TBL] [Abstract][Full Text] [Related]
29. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
[TBL] [Abstract][Full Text] [Related]
31. The current status of therapeutic HPV vaccine.
van Driel WJ; Ressing ME; Brandt RM; Toes RE; Fleuren GJ; Trimbos JB; Kast WM; Melief CJ
Ann Med; 1996 Dec; 28(6):471-7. PubMed ID: 9017105
[TBL] [Abstract][Full Text] [Related]
32. [Human papillomavirus as an etiological factor in cervical cancer: significance for health care practice].
Kiselev FL
Vopr Virusol; 1997; 42(6):248-51. PubMed ID: 9499235
[No Abstract] [Full Text] [Related]
33. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.
Oka Y; Sugiyama H
Immunotherapy; 2010 Sep; 2(5):591-4. PubMed ID: 20874639
[No Abstract] [Full Text] [Related]
34. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
35. Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.
Street D; Kaufmann AM; Vaughan A; Fisher SG; Hunter M; Schreckenberger C; Potkul RK; Gissmann L; Qiao L
Gynecol Oncol; 1997 May; 65(2):265-72. PubMed ID: 9159336
[TBL] [Abstract][Full Text] [Related]
36. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.
Evans EM; Man S; Evans AS; Borysiewicz LK
Cancer Res; 1997 Jul; 57(14):2943-50. PubMed ID: 9230206
[TBL] [Abstract][Full Text] [Related]
37. [Viral infection and cervix carcinoma].
Schneweis KE
Gynakologe; 1984 Jun; 17(2):84-7. PubMed ID: 6088372
[No Abstract] [Full Text] [Related]
38. Treg cells in different forms of uterine cancer.
Hou F; Ma D; Cui B
Clin Chim Acta; 2013 Jan; 415():337-40. PubMed ID: 23178746
[TBL] [Abstract][Full Text] [Related]
39. Serological response to HPV 16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer.
Ghosh AK; Smith NK; Stacey SN; Glew SS; Connor ME; Arrand JR; Stern PL
Int J Cancer; 1993 Feb; 53(4):591-6. PubMed ID: 8382193
[TBL] [Abstract][Full Text] [Related]
40. [Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice].
Zhao J; Lu J; Liu YQ; Yang HY; Huang YT; Zhao JM; Li S; Zhai JM; Zhao MY; Zhang X; Dong ZM
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):52-7. PubMed ID: 21429436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
